.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB10_PeginterferonAlfa2b.PeginterferonAlfa2b .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB10_PeginterferonAlfa2b.PeginterferonAlfa2b| name: | PeginterferonAlfa2b |
| ATC code: | L03AB10 | route: | subcutaneous |
| n-compartments | 1 |
Peginterferon alfa-2b is a pegylated recombinant interferon used as an antiviral and antineoplastic agent, primarily in the treatment of chronic hepatitis C and B infections. It has also been explored in some malignancies. While widely used in the 2000s and 2010s, direct-acting antivirals have largely replaced it in hepatitis C therapy. It remains approved and is occasionally used today in specific settings.
Pharmacokinetic parameters in adult patients with chronic hepatitis C receiving subcutaneous doses.
Xu, C, et al., & Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. European journal of clinical pharmacology 69(12) 2045–2054. DOI:10.1007/s00228-013-1574-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23975236
Miyachi, N, et al., & Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. Clinical drug investigation 41(4) 391–404. DOI:10.1007/s40261-021-01026-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33725322
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650